PEYRON-MATHERON

PEYRON-MATHERON, a company founded by Charles Raymond Peyron in Embrun, is a leading player in the field of parasitology research. Specializing in the development of high-throughput growth assays for the protozoan parasite Toxoplasma gondii, the company's core products include a highly fluorescent transgenic parasite line stably transfected with a tandem yellow fluorescent protein (YFP). This innovative technology enables accurate measurement of parasite numbers in microtiter plates, offering a more efficient and less toxic approach to antiparasitic drug screening.

With a strong industry position and market presence, PEYRON-MATHERON stands out for its cutting-edge approach to parasite research. The company's key differentiators lie in the high sensitivity and accuracy of its YFP growth assay, especially at higher parasite concentrations, as well as its ability to monitor delayed parasite death kinetics and drug resistance development. These unique value propositions have led to notable achievements in the field, including the determination of 50%-inhibitory concentrations of growth-inhibiting drugs and the temperature-dependent effect of certain medications on parasite growth.

PEYRON-MATHERON's target markets include the pharmaceutical and biotechnology industries, where its advanced technology and versatile assay methods have garnered significant interest. The company's commitment to innovation, coupled with its mission to develop more effective and safe antiparasitic drugs, drives its strategic direction. As it continues to expand its geographic presence and enhance its leadership approach, PEYRON-MATHERON is poised to make further advancements in the field of parasitology research, offering promising prospects for the future of antiparasitic drug development.